Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Journal of Hepatology|September 20, 2012
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO studyAziz Zaanan, Nicolas Williet, Mohamed Hebbar, et al.
Journal of Hepatology|March 15, 2012
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cellsMarie-José Blivet-Van Eggelpoël, Hamza Chettouh, Laetitia Fartoux, et al.
Histopathology|July 9, 2016
Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosisMarie Lequoy, Christèle Desbois-Mouthon, Dominique Wendum, et al.
Cancer Letters|March 9, 2019
Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell featuresEva Benabou, Zeina Salamé, Dominique Wendum, et al.
Cancer Research|May 2, 2013
Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factorsHamza Chettouh, Laetitia Fartoux, Lynda Aoudjehane, et al.
Free Radical Biology & Medicine|July 15, 2015
Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cellsThanh Huong Nguyen Ho-Bouldoires, Audrey Clapéron, Martine Mergey, et al.
Hepatology (Baltimore, Md.)|May 24, 2007
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroidsAlexandre Louvet, Sylvie Naveau, Marcelle Abdelnour, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 13, 2016
Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulinCorina Buta, Eva Benabou, Marie Lequoy, et al.
Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2021
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trialArndt Vogel, Shukui Qin, Masatoshi Kudo, et al.
Pageof 4